Supplementary Table 1. List of Efficacy Endpoints in MONARCH

Primary endpoint	Change from baseline in DAS28-ESR at week 24

Secondary endpoints*	DAS28-ESR remission (<2.6) at week 24
	ACR20, ACR50, and ACR70 response at week 24
	Change from baseline in HAQ-DI at week 24
	Change from baseline in SF-36 (physical and mental components) at week 24
	Change from baseline in FACIT-F at week 24
	DAS28-ESR low disease activity (<3.2) at week 24
	Change from baseline in each individual ACR component at week 24
	Change from baseline in DAS28-CRP at weeks 12 and 24
	DAS28-CRP remission (<2.6) at week 24
	DAS28-CRP low disease activity (<3.2) at week 24
	Change from baseline in CDAI at weeks 12 and 24
	CDAI remission (≤2.8) at weeks 12 and 24

*Items above the dotted line were part of the hierarchy; items below the dotted line were prespecified secondary endpoints. All primary and secondary endpoints were also analyzed at week 12.
ACR, American College of Rheumatology; CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; DAS28-CRP, 28-joint disease activity score using CRP; DAS28-ESR, DAS28 using erythrocyte sedimentation rate; FACIT-F, Functional Assessment of Chronic Illness Therapy–Fatigue; HAQ-DI, Health Assessment Questionnaire–Disability Index; SF-36, Short Form 36 Health Survey.